Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer’s Dementia in Individuals With Previous Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression is associated with an increased risk of Alzheimer's disease. Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases amyloid-β generation and plaque load. The authors evaluated the impact of SSRI treatment on CSF biomarkers and progression from mild cognitive impairment (MCI) to Alzheimer's dementia. METHOD: Data sets from 755 currently nondepressed participants from the longitudinal Alzheimer's Disease Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covariance with ApoE4 status and age as covariates. RESULTS: In MCI patients with a history of depression, long-term SSRI treatment (>4 years) was significantly associated with a delayed progression to Alzheimer's dementia by approximately 3 years, compared with short-term SSRI treatment, treatment with other antidepressants, or no treatment and compared with MCI patients without a history of depression. No differences in CSF biomarker levels were observed between treatment groups. CONCLUSIONS: Long-term SSRI treatment may delay progression from MCI to Alzheimer's dementia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study found that more than 4 years of such treatment was associated with delayed progression to clinically diagnosed Alzheimer's disease.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [119]
In the citing paper
“and long-term treatment with antidepressants delays the conversion of mild cognitive impairment to Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
In the citing paper
“Recent findings suggest that SSRIs may delay the onset of Alzheimer’s dementia119.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [119]
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“A growing body of evidence points toward a complex role of neuroinflammation in amyloidogenesis, neurodegeneration, and cognitive decline (41).”
Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., Suridjan, I., Kennedy, J. L., Rekkas, P. V., Houle, S., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2427 · Cited by 939 · cited 1×
“Neuroinflammation has also been detected in patients during major depressive episodes (42, 43).”
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Modrego, P. J., & Ferrández, J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1290 · Cited by 537 · cited 1×
“This is in contrast to anotherprospectivecohort (30) inwhichahigher rateofMCI progression to Alzheimer’s dementia was found to be associated with depression.”
Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., Bentham, P., Fox, C., Holmes, C., Katona, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60830-1 · Cited by 532 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Depressive symptoms, cognitive decline, and risk of AD in older persons
Wilson, R. S., Barnes, L. L., Mendes de Leon, C. F., Aggarwal, N. T., Schneider, J. S., Bach, J., Pilat, J., Beckett, L. A., Arnold, S. E., Evans, D. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.3.364 · Cited by 528 · cited 1×
“Other studies have found that the severity of depression at baseline was correlated with risk of developing dementia (31).”
Shelton, R. C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D. A., & Mirnics, K. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.52 · Cited by 511 · cited 1×
“Neuroinflammation has also been detected in patients during major depressive episodes (42, 43).”
Depressive symptoms and risk of dementia: The Framingham Heart Study
Saczynski, J. S., Beiser, A., Seshadri, S., Auerbach, S., Wolf, P. A., & Au, R. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62138 · Cited by 488
Yaffe, K. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1481 · Cited by 445
Molendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.98 · Cited by 437
Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor
Anacker, C., Zunszain, P. A., Cattaneo, A., Carvalho, L. A., Garabedian, M. J., Thuret, S., Price, J., & Pariante, C. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.26 · Cited by 435 · cited 1×
“, by modulation of neuroinflammation (35, 36), acetylcholine release (37, 38), or neurodegeneration or neurogenesis (39), although itmust be taken into account that changes in a-secretase activity are not always paralleled by effects on b-secretase (BACE) cleavage products (40).”
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment
Dotson, V. M., Beydoun, M. A., & Zonderman, A. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e62124 · Cited by 385 · cited 1×
“A recent study (7) demonstrated that ahistory of recurrent depressive episodes was strongly associated with a cumulatively increasing risk of subsequent Alzheimer’s dementia.”
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 3×
“If SSRI treatment conferred its beneficial effect by inhibiting amyloid-b1–42 generation, as has been proposed (12, 15), CSF levels of amyloidogenic APP cleavage products, such as soluble APP sAPP-b (28) and CSF amyloid-b1–42, should be lower in the SSRI treatment group.”
Palmer, K., Di Iulio, F., Varsi, A. E., Gianni, W., Sancesario, G., Caltagirone, C., & Spalletta, G. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1352 · Cited by 290 · cited 1×
“Similar to previous findings (29), we did not observe a higher rate of conversion of MCI to Alzheimer’s dementia in participants with a history of depression compared with those without a history of depression.”
Mourao, R. J., Mansur, G., Malloy‐Diniz, L. F., Castro Costa, E., & Diniz, B. S. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4406 · Cited by 256
Novel therapeutic approaches beyond the serotonin receptor
Duman, R. S. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00031-6 · Cited by 239 · cited 1×
“Compelling evidence demonstrates that neurogenesis is impaired in depression, a phenomenon likely mediated by a decrease of BDNF and vascularendothelialgrowthfactor(VEGF)(49).”
Higher brain BDNF gene expression is associated with slower cognitive decline in older adults
Buchman, A. S., Yu, L., Boyle, P. A., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002387 · Cited by 239 · cited 1×
“Decreasedlevelsof BDNF have also been described in Alzheimer’s disease and, conversely, high levels of brain BDNF have been found to be associated with lower rates of cognitive decline (50).”
An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study
Yasar, S., Xia, J., Yao, W., Furberg, C. D., Xue, Q.-L., Mercado, C. I., Fitzpatrick, A. L., Fried, L. P., Kawas, C. H., Sink, K. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a35228 · Cited by 214
Walker, F. R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.002 · Cited by 175 · cited 2×
“SSRIs canmodulate key inflammatory factors, such as tumor necrosis factor alpha (36), interleukins-1b and -6, and reactive oxygen stress.”
Clinical-pathologic study of depressive symptoms and cognitive decline in old age
Wilson, R. S., Capuano, A. W., Boyle, P. A., Hoganson, G. M., Hizel, L. P., Shah, R. C., Nag, S., Schneider, J. A., Arnold, S. E., & Bennett, D. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000715 · Cited by 165
Mowla, A., Mosavinasab, M., & Pani, A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e0002 · Cited by 141
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin
Endres, K., Fahrenholz, F., Lotz, J., Hiemke, C., Teipel, S., Lieb, K., Tüscher, O., & Fellgiebel, A. (2014) · Neurology · doi:10.1212/wnl.0000000000001017 · Cited by 137 · cited 1×
“In a trialwith thea-secretase activator acitretin (34), no changes in steady-state CSF amyloid-b1–42 concentrations were observed, although thea-secretase cleavageproduct soluble APP-a (sAPP-a) was increased in CSF.”
VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux
Mohler, E. G., Shacham, S., Noiman, S., Lezoualc’h, F., Robert, S. J., Gastineau, M., Rutkowski, J., Marantz, Y., Dumuis, A., Bockaert, J., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.016 · Cited by 103 · cited 1×
“, by modulation of neuroinflammation (35, 36), acetylcholine release (37, 38), or neurodegeneration or neurogenesis (39), although itmust be taken into account that changes in a-secretase activity are not always paralleled by effects on b-secretase (BACE) cleavage products (40).”
Wharton, W., Goldstein, F. C., Zhao, L., Steenland, K., Levey, A. I., & Hajjar, I. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13627 · Cited by 89
Vollmar, P., Nessler, S., Kalluri, S. R., Hartung, H.-P., & Hemmer, B. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009425 · Cited by 87 · cited 1×
“Interestingly, in a mouse model, SSRIswere found to ameliorate experimental allergic encephalitis–induced symptoms (44, 45).”
Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions
Villeneuve, S., Reed, B. R., Madison, C. M., Wirth, M., Marchant, N. L., Kriger, S., Mack, W. J., Sanossian, N., DeCarli, C., Chui, H. C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000550 · Cited by 87 · cited 1×
“The underlying reasons are still a matter of debate, but possibilities include depression as a disease prodrome, an early symptom, a bona fide risk factor, or a confounder associated with comorbidities, such as vascular disease, that themselves predispose to Alzheimer’s dementia (10, 11).”
Fluoxetine and S-citalopram inhibit M1 activation and promote M2 activation of microglia in vitro
Su, F., Yi, H., Xu, L., & Zhang, Z. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.02.028 · Cited by 86 · cited 1×
“, by modulation of neuroinflammation (35, 36), acetylcholine release (37, 38), or neurodegeneration or neurogenesis (39), although itmust be taken into account that changes in a-secretase activity are not always paralleled by effects on b-secretase (BACE) cleavage products (40).”
Qiao, J., Wang, J., Wang, H., Zhang, Y., Zhu, S., Adilijiang, A., Guo, H., Zhang, R., Guo, W., Luo, G., et al. (2016) · Glia · doi:10.1002/glia.22926 · Cited by 80 · cited 1×
“Inhibition of amyloid-b1–42 production was also observed on treatment of astrocytes with fluoxetine in vitro, paralleled by decreased astrocytic activation (32).”
Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo
Fisher, J. R., Wallace, C. E., Tripoli, D. L., Sheline, Y. I., & Cirrito, J. R. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0112-5 · Cited by 80
Shen, F., Smith, J. A. M., Chang, R., Bourdet, D. L., Tsuruda, P. R., Obedencio, G. P., & Beattie, D. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.026 · Cited by 79
Do continued antidepressants protect against dementia in patients with severe depressive disorder?
Kessing, L. V., Forman, J. L., & Andersen, P. K. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834ace0f · Cited by 74
Role of 5-HT4 Receptors in the Mouse Passive Avoidance Test
Galeotti, N., Ghelardini, C., & Bartolini, A. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37700-6 · Cited by 74 · cited 1×
“5-HT4 receptor stimulation has been shown to increase acetylcholine release and to counteract the cognitive impairment induced by anticholinergic drugs (46, 47).”
Taler, M., Gil-Ad, I., Korob, I., & Weizman, A. (2011) · Neuroimmunomodulation · doi:10.1159/000321634 · Cited by 64 · cited 1×
“Interestingly, in a mouse model, SSRIswere found to ameliorate experimental allergic encephalitis–induced symptoms (44, 45).”
Colombo, A., Wang, H., Kuhn, P.-H., Page, R., Kremmer, E., Dempsey, P. J., Crawford, H. C., & Lichtenthaler, S. F. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.08.011 · Cited by 62
Mokhber, N., Abdollahian, E., Soltanifar, A., Samadi, R., Saghebi, A., Haghighi, M., & Azarpazhooh, A. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1377041 · Cited by 61 · cited 1×
“Several randomized and placebocontrolled studies have evaluated the effect of SSRIs on cognition in Alzheimer’s dementia, finding either favorable effects (16, 17), no effects (18–20), or even disadvantageous effects of SSRI treatment (21, 22).”
Matchkov, V. V., Kravtsova, V. V., Wiborg, O., Aalkjaer, C., & Bouzinova, E. V. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00337.2014 · Cited by 55
Brodney, M. A., Johnson, D. E., Sawant‐Basak, A., Coffman, K. J., Drummond, E. M., Hudson, E., Fisher, K. E., Noguchi, H., Waizumi, N., McDowell, L. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300953p · Cited by 54 · cited 1×
“, by modulation of neuroinflammation (35, 36), acetylcholine release (37, 38), or neurodegeneration or neurogenesis (39), although itmust be taken into account that changes in a-secretase activity are not always paralleled by effects on b-secretase (BACE) cleavage products (40).”
Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease
Munro, C. A., Longmire, C. F., Drye, L. T., Martin, B. K., Frangakis, C. E., Meinert, C. L., Mintzer, J. E., Porsteinsson, A. P., Rabins, P. V., Rosenberg, P. B., et al. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31826ce4c5 · Cited by 49
CNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition
Dobrowolska, J. A., Michener, M. S., Wu, G., Patterson, B. W., Chott, R., Ovod, V., Pyatkivskyy, Y., Wildsmith, K. R., Kasten, T., Mathers, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0540-14.2014 · Cited by 37
Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex
Wu, G., Sankaranarayanan, S., Hsieh, S. H.-K., Simon, A. J., & Savage, M. J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22618 · Cited by 33
Choe, Y. M., Kim, K. W., Jhoo, J. H., Ryu, S. H., Seo, E. H., Sohn, B. K., Byun, M. S., Bak, J., Lee, J., Yun, H. J., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4384 · Cited by 31 · cited 1×
“With one exception (18), these studies covered only short time spans, ranging from 8 to 24 weeks.”
Tsiouris, J. A., Patti, P. J., & Flory, M. J. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08562 · Cited by 23 · cited 1×
“In contrast, another retrospective study (24) found that antidepressant”
Fontana, D. J., Daniels, S. E., Eglen, R. M., & Wong, E. H. F. (1996) · Neuropharmacology · doi:10.1016/0028-3908(96)00191-8 · Cited by 17 · cited 1×
“5-HT4 receptor stimulation has been shown to increase acetylcholine release and to counteract the cognitive impairment induced by anticholinergic drugs (46, 47).”
Emilsson, J. F., Andréasson, U., Blennow, K., Eriksson, E., & Zetterberg, H. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010053 · Cited by 10 · cited 1×
“Lower production rates of CSF amyloid-b1–42 have been observed in healthy volunteers after acute administration of citalopram (15), although another study obtained conflicting results (33).”
Research works printed but not linked: 1
- Bubu OM, Sleep
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedThe Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention
Zhang, X.-X., Tian, Y., Wang, Z.-T., Ma, Y.-H., Tan, L., & Yu, J.-T. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.15 · Cited by 789
“In addition, treatment with the citalopram for more than 4 years was strongly linked to a 3-year delay in progression from mild cognitive impairment (MCI) to AD (25).”
InfluentialMechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312
Metadata
- Authors
- Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N.
- Affiliations
- University of Bonn (DE)
- Venue
- American Journal of Psychiatry
- Published
- 2018-03-01
- Volume
- 175
- Issue
- 3
- Pages
- 232-241
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2768441608
- Semantic Scholar
- 84cf627e767f53e0918c5ac480be02106899308f
- Cited by
- 202
- References
- 50
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 26 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 15 · 2019: 19 · 2018: 15
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (publishedVersion)
- Max Planck Digital Library (submittedVersion)
- GRO (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- selective serotonin reuptake inhibitors, citalopram, mild cognitive impairment, Alzheimer's disease, conversion to dementia, history of depression, cerebrospinal fluid biomarkers, amyloid-beta, APOE ε4, antidepressant treatment duration, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Alzheimer Disease, Depression, Humans, Risk Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Kaplan-Meier Estimate, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.